Intelligence · Patents
Patents expiring in 2037
Annual patent cliff calendar for 2037 — US pharmaceutical patents by expiration date.
- Patents
- 1,615
Quick answer
1,615 indexed pharmaceutical patents have expiration dates in 2037. Browse by soonest expiry with links to assignee companies and related drugs.
-
US 9650607
Modalities for the treatment of degenerative diseases of the retina
granted -
US 9650447
Complement receptor 2 (CR2) targeting groups
granted -
US 9650444
Anti-PDGFR-beta antibodies and uses thereof
granted -
US 9650422
Localization and characterization of flavivirus envelope glycoprotein cross-reactive epitopes and methods for their use
granted -
US 9650417
Treatments for gastrointestinal disorders
granted -
US 9650395
Antibacterial compounds and methods for use
granted -
US 9650352
Use of (2R, 6R)-hydroxynorketamine, (S)-dehydronorketamine and other stereoisomeric dehydro and hydroxylated metabolites of (R,S)-ketamine in the treatment of depression and neuropathic pain
granted -
US 9650365
Itraconazole analogues and methods of use thereof
granted -
US 9650342
Compositions and methods of treating retinal disease
granted -
US 9649340
Methods for producing enriched populations of human retinal pigment epithelium cells
granted -
US 9649344
Methods and compositions for in vivo induction of pancreatic beta cell formation
granted -
US 9649358
Methods for use of neural stem cell compositions for treatment of central nervous system lesions
granted -
US 9649373
Neoseptins: small molecule adjuvants
granted -
US 9649339
LAT adapter molecule for enhanced T-cell signaling and method of use
granted -
US 9649327
Composition of novel carbohydrate drug for treatment of human diseases
granted -
US 9649321
Phosphonate compounds
granted -
US 9649284
Treating critically ill patients with intravenous ibuprofen
granted -
US 9648899
Drinking water formulation and method and article relating to same
granted -
US 2017136004
Opioid Agonist Antagonist Combinations
granted -
US 9657269
Regulatory B cells (tBREGS) and their use
granted -
US 9657096
Human domain antibodies against components of the human insulin-like growth factor (IGF) system
granted -
US 9657090
Method of treating alveolar bone loss through the use of anti-sclerostin antibodies
granted -
US 9655909
Personalized medicine for the prediction of therapy targeting the hedgehog pathway
granted -
US 9656001
Anti-adhesive barrier membrane using alginate and hyaluronic acid for biomedical applications
granted -
US 9657012
FAAH inhibitors
granted -
US 9655352
Humanized M-CSF mice
granted -
US 9658230
Antibodies or fragments thereof directed against a Staphylococcus aureus epitope of IsaA or IsaB
granted -
US 9657292
Compositions and methods for treating or preventing lupus
granted -
US 9657288
Connector compound peptide phage display
granted -
US 9657270
Human disc tissue
granted -
US 9657267
Ex host maturation of germline stem cells
granted -
US 9657102
Anti-CD3 antibodies, bispecific antigen-binding molecules that bind CD3 and CD20, and uses thereof
granted -
US 9657099
Anti-glucagon antibodies
granted -
US 9655969
Inhalable medicament comprising tiotropium
granted -
US 9657066
Pseudomonas exotoxin A with less immunogenic B cell epitopes
granted -
US 9657023
Polymorph of Syk inhibitors
granted -
US 9657007
Substituted aminopyrimidine compounds and methods of use
granted -
US 9656999
Therapeutically active compounds and their methods of use
granted -
US 9657004
Pyruvate kinase M2 modulators, therapeutic compositions and related methods of use
granted -
US 9656993
Crystalline forms of a biphenyl compound
granted -
US 9655917
Immobilization of an active agent on a substrate using compounds including trihydroxyphenyl groups
granted -
US 9655881
Nitrogen-containing heterocyclic compound
granted -
US 9655938
Compositions of polymeric myrcene
granted -
US 9655900
Heterocyclic compound
granted -
US 9655842
Injectable non-aqueous compositions and methods of treating vascular disease
granted -
US 9655366
Volatile blends and the effects thereof on the navel orangeworm moth
granted -
EP 3169322
DIÄTETISCHE ZUSAMMENSETZUNG MIT ANTIDYSLIPIDÄMISCHER AKTIVITÄT
granted -
US 9663504
Salts of heterocyclic modulators of HIF activity for treatment of disease
granted
Frequently asked questions
How many pharma patents expire in 2037?
1,615 published patents in our USPTO index have expiration dates falling in calendar year 2037.